Page 1

EX - 99.1 2 dyn - ex991_7.htm EX - 99.1 YDyne THERAPEUTICS Exhibit 99.1 Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights - On Track to Submit INDs for DM1 , DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - - Well - Resourced with Cash Runway Expected into the Second Half of 2024 - - WALTHAM , Mass . , May 6 , 2021 – Dyne Therapeutics , Inc. ( Nasdaq : DYN ) , a muscle disease company focused on advancing innovative life - transforming therapeutics for people living with genetically driven diseases , today reported financial results for the first quarter 2021 and business highlights . " We continued to make significant progress to start 2021 , including generating new preclinical data in our DM1 program that will be featured during the upcoming ASGCT Annual Meeting , further strengthening our leadership team with key appointments and enhancing our financial foundation with cash runway expected into the second half of 2024 , ” said Joshua Brumm , president and chief executive officer of Dyne . " We are focused on executing across all aspects of the business as we drive our three programs to the clinic , advance our efforts to deliver life - transforming therapies to patients and pursue our goal of building the world's leading muscle disease company . " Upcoming Events & Presentations New preclinical data from Dyne's myotonic dystrophy type 1 ( DM1 ) program will be featured in presentations during the American Society of Gene & Cell Therapy_ ( ASGCT ) 24th Annual Meeting , to be held virtually May 11-14 , 2021 . The presentations will include new data , expanding upon initial findings reported in January 2021 utilizing an innovative hTfR1 / DMSXL mouse model developed by Dyne , as well as results from in vitro studies . Romesh Subramanian , Ph.D. , chief scientific officer , will present on Splice Correction and Reduction of Toxic DMPK RNA In Vitro and In Vivo Utilizing Novel Antibody Targeted Antisense Oligonucleotides during the " Hot Topics and Remaining Challenges in RNAi and Oligonucleotide Therapy for 2021 " scientific symposium , on Friday , May 14 , 2021 , at 10:26 a.m. ET . Stefano Zanotti , Ph.D. , director , mechanistic biology , is scheduled to deliver an oral presentation on Friday , May 14 , 2021 , at 1:15 p.m. ET , entitled The FORCETM Platform Achieves Robust Knock Down of Toxic Human Nuclear DMPK RNA and Foci Reduction in DM1 Cells and in Newly Developed hTfR1 / DMSXL Mouse Model . Following the ASGCT presentations , Dyne plans to host a live webcast event on May 14 , 2021 at 4:00 p.m. ET to review the company's DM1 program and preclinical data , and to provide an overview of the disease and treatment challenges . Joining management on the call will be Charles Thornton , M.D. , the Saunders Distinguished Professor of Neuromuscular Research at the University of Rochester , and a leading expert in DM1 . The live event and replay will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/investors-and- media . 1